Solasia Pharma K.K. (TYO:4597)
Japan · Delayed Price · Currency is JPY 29.00
-2.00 (-6.45%)
Aug 25, 2026, 3:30 PM JST
Solasia Pharma K.K. Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 388 | 429 | 316 | 617 | 1,092 | 559 | |
Revenue Growth | 32.42% | 35.76% | -48.78% | -43.50% | 95.35% | 23.13% |
Cost of Revenue | 193 | 221 | 131 | 280 | 430 | 185 |
Gross Profit | 195 | 208 | 185 | 337 | 662 | 374 |
Selling, General & Admin | 659 | 637 | 1,721 | 1,073 | 2,250 | 1,948 |
Research & Development | 428 | 430 | 414 | 403 | 883 | 845 |
Operating Expenses | 1,087 | 1,067 | 2,135 | 1,476 | 3,133 | 2,793 |
Operating Income | -892 | -859 | -1,950 | -1,139 | -2,471 | -2,419 |
Interest Expense | -5 | -14 | -5 | - | -18 | -23 |
Interest & Investment Income | 2 | 1 | - | 10 | - | - |
Earnings From Equity Investments | -1 | -1 | -4 | -5 | -3 | - |
Other Non Operating Income (Expenses) | -4 | -3 | -1 | -1 | - | -1 |
Pretax Income | -900 | -876 | -1,960 | -1,135 | -2,492 | -2,443 |
Income Tax Expense | - | - | -19 | -23 | 56 | 35 |
Net Income | -900 | -876 | -1,941 | -1,112 | -2,548 | -2,478 |
Net Income to Common | -900 | -876 | -1,941 | -1,112 | -2,548 | -2,478 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 263 | 238 | 199 | 168 | 152 | 130 |
Shares Outstanding (Diluted) | 263 | 238 | 199 | 168 | 152 | 130 |
Shares Change | 21.43% | 19.53% | 18.18% | 10.62% | 16.78% | 10.88% |
EPS (Basic) | -3.42 | -3.69 | -9.77 | -6.61 | -16.76 | -19.04 |
EPS (Diluted) | -3.42 | -3.69 | -9.77 | -6.62 | -16.77 | -19.04 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,140 | -847 | -1,034 | -359 | -2,074 | -2,475 |
Free Cash Flow Per Share | -4.33 | -3.57 | -5.20 | -2.13 | -13.65 | -19.02 |
Gross Margin | 50.26% | 48.48% | 58.54% | 54.62% | 60.62% | 66.91% |
Operating Margin | -229.90% | -200.23% | -617.09% | -184.60% | -226.28% | -432.74% |
Profit Margin | -231.96% | -204.20% | -614.24% | -180.23% | -233.33% | -443.29% |
Free Cash Flow Margin | -293.81% | -197.44% | -327.21% | -58.18% | -189.93% | -442.75% |
EBITDA | -855 | -822 | -1,755 | -639 | -1,937 | -1,924 |
EBITDA Margin | -220.36% | -191.61% | - | -103.57% | -177.38% | - |
D&A For EBITDA | 37 | 37 | 195 | 500 | 534 | 495 |
EBIT | -892 | -859 | -1,950 | -1,139 | -2,471 | -2,419 |
EBIT Margin | -229.90% | -200.23% | - | -184.60% | -226.28% | - |